South Korea’s HLB is gaining speed in its plan to commercially develop a targeted anticancer therapy called Rivoceranib through a triangular merger involving its U.S. affiliate and the drug’s original developer Elevar.

Source: https://pulsenews.co.kr/view.php?year=2019&no=839136